Literature DB >> 33649796

lncRNA ST3GAL6‑AS1 promotes invasion by inhibiting hnRNPA2B1‑mediated ST3GAL6 expression in multiple myeloma.

Ying Shen1, Yuandong Feng1, Fangmei Li1, Yachun Jia1, Yue Peng1, Wanhong Zhao1, Jinsong Hu2, Aili He1.   

Abstract

Multiple myeloma (MM) is an incurable disease caused by the infiltration of malignant plasma B cells into bone marrow, whose pathogenesis remains largely unknown. Long non‑coding RNAs (lncRNAs) have emerged as important factors in pathogenesis. Our previous study validated that lncRNA ST3 β‑galactoside α‑2,3‑sialyltransferase 6 antisense RNA 1 (ST3GAL6‑AS1) was upregulated markedly in MM. Therefore, the aim of the study was to investigate the molecular mechanisms of ST3GAL6‑AS1 in MM cells. ST3GAL6‑AS1 expression levels in MM cells was detected using reverse transcription‑quantitative PCR. ST3GAL6‑AS1 antisense oligonucleotides and small interfering RNAs were transfected into MM cells to downregulate expression. In vitro assays were performed to investigate the functional role of ST3GAL6‑AS1 in MM cells. RNA pull‑down, RNA immunoprecipitation and comprehensive identification of RNA‑binding proteins using mass spectrometry assays were used to determine the mechanism of ST3GAL6‑AS1‑mediated regulation of underlying targets. It was reported that knockdown of ST3GAL6‑AS1 suppressed the adhesion, migration and invasion ability of MM cells in vitro. Expression of ST3GAL6 was significantly reduced when ST3GAL6‑AS1 was knock downed in MM cells. Moreover, mechanistic investigation showed that ST3GAL6‑AS1 could suppress ST3GAL6 mRNA degradation via interacting with heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1). The present results suggested that upregulated lncRNA ST3GAL6‑AS1 promotes adhesion and invasion of MM cells by binding with hnRNPA2B1 to regulate ST3GAL6 expression.

Entities:  

Keywords:  multiple myeloma; ST3GAL1-AS1; adhesion; invasion; heterogeneous nuclear ribonucleoprotein A2B1; ST3GAL6

Mesh:

Substances:

Year:  2021        PMID: 33649796      PMCID: PMC7895539          DOI: 10.3892/ijo.2021.5185

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  47 in total

Review 1.  The mechanism and clinical significance of long noncoding RNA-mediated gene expression via nuclear architecture.

Authors:  Jian Shi; Yan-ming Li; Xiang-dong Fang
Journal:  Yi Chuan       Date:  2017-03-20

Review 2.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

3.  Deregulated expression of long non-coding RNA UCA1 in multiple myeloma.

Authors:  Lenka Sedlarikova; Barbora Gromesova; Veronika Kubaczkova; Lenka Radova; Jana Filipova; Jiri Jarkovsky; Lucie Brozova; Roberta Velichova; Martina Almasi; Miroslav Penka; Renata Bezdekova; Martin Stork; Zdenek Adam; Ludek Pour; Marta Krejci; Petr Kuglík; Roman Hajek; Sabina Sevcikova
Journal:  Eur J Haematol       Date:  2017-06-29       Impact factor: 2.997

4.  Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.

Authors:  W P Tsang; T T Kwok
Journal:  Oncogene       Date:  2007-02-05       Impact factor: 9.867

5.  Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression.

Authors:  Ming Luo; Zuowei Li; Wei Wang; Yigang Zeng; Zhihong Liu; Jianxin Qiu
Journal:  Cancer Lett       Date:  2013-01-24       Impact factor: 8.679

Review 6.  Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2020-05       Impact factor: 10.047

7.  MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression.

Authors:  Shih-Feng Cho; Yuli Christine Chang; Chao-Sung Chang; Sheng-Fung Lin; Yi-Chang Liu; Hui-Hua Hsiao; Jan-Gowth Chang; Ta-Chih Liu
Journal:  BMC Cancer       Date:  2014-11-04       Impact factor: 4.430

8.  Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.

Authors:  Meng Zhou; Hengqiang Zhao; Zhenzhen Wang; Liang Cheng; Lei Yang; Hongbo Shi; Haixiu Yang; Jie Sun
Journal:  J Exp Clin Cancer Res       Date:  2015-09-11

Review 9.  The hnRNP family: insights into their role in health and disease.

Authors:  Thomas Geuens; Delphine Bouhy; Vincent Timmerman
Journal:  Hum Genet       Date:  2016-05-23       Impact factor: 4.132

Review 10.  Phylogenetic-Derived Insights into the Evolution of Sialylation in Eukaryotes: Comprehensive Analysis of Vertebrate β-Galactoside α2,3/6-Sialyltransferases (ST3Gal and ST6Gal).

Authors:  Roxana E Teppa; Daniel Petit; Olga Plechakova; Virginie Cogez; Anne Harduin-Lepers
Journal:  Int J Mol Sci       Date:  2016-08-09       Impact factor: 5.923

View more
  2 in total

1.  Comprehensive landscape of the ST3GAL family reveals the significance of ST3GAL6-AS1/ST3GAL6 axis on EGFR signaling in lung adenocarcinoma cell invasion.

Authors:  Jiaxuan Li; Yiming Long; Jingya Sun; Jiajun Wu; Xiao He; Simei Wang; Xiongbiao Wang; Xiayi Miao; Ruimin Huang; Jun Yan
Journal:  Front Cell Dev Biol       Date:  2022-08-26

2.  Upregulation of the novel lncRNA U731166 is associated with migration, invasion and vemurafenib resistance in melanoma.

Authors:  Ádamo Davi Diógenes Siena; Isabela Ichihara de Barros; Camila Baldin Storti; Carlos Alberto Oliveira de Biagi Júnior; Larissa Anastacio da Costa Carvalho; Silvya Stuchi Maria-Engler; Josane de Freitas Sousa; Wilson Araújo Silva
Journal:  J Cell Mol Med       Date:  2022-01-18       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.